Olipharma Officially Launches on CASmart Platform and Files IPO Prospectus

Suzhou Olipharma Technology Co., Ltd. is a professional pharmaceutical nucleic acid CDMO company that provides customers with "one-stop" services including nucleic acid drug discovery, laboratory R&D, process and analytical development, CMC services, API production, and drug registration. The technical team of Olipharma comes from one of the earliest teams in China to engage in the development of nucleic acid drug manufacturing processes and CMC research, possessing extensive experience in project development and product registration. Currently, the company has built four industry-leading core technology platforms: nucleic acid solid-phase synthesis, chemical modification and conjugation, process development and analysis, and CMC pharmaceutical research. It has also established in-depth collaborations with multiple pharmaceutical companies and biotechnology firms both domestically and internationally.

In 2023, the company's 3,000㎡ pilot platform compliant with GMP standards officially began offering services, focusing on helping clients address critical challenges such as the scale-up of small nucleic acid drug production processes and CMC pharmaceutical research. The company will continue to provide high-quality, reliable, and efficient services to help clients improve R&D efficiency, accelerate product registration and market entry, jointly supporting the entire process of small nucleic acid drugs from preclinical to commercial production.